Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema

Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema

By: Latest Articles from Benzinga.com

Posted on December 06, 2012 at 06:17 AM EST

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that Bayer HealthCare (OTC: BAYRY ) has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO). "It is our pleasure to announce

Related Stocks:

Bayer Aktiengesellschaft American Depositary Shares GBL INV HSE NewStar Financial, Inc. Regeneron Pharmaceuticals, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates